Journal profile · MEDICINE, RESEARCH & EXPERIMENTAL
Biomolecules and Biomedicine
ISSN 2831-0896 · eISSN 2831-090X · Association of Basic Medical Sciences of FBIH
Biomolecules and Biomedicine: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.8 (journal website); fully open access; APC charged, amount not published; median 57 days to acceptance (106 articles, last 24 months); 214 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Biomolecules and Biomedicine is published by Association of Basic Medical Sciences of FBIH and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Ferroptosis and cancer prognosis, Inflammatory Biomarkers in Disease Prognosis and Cancer Immunotherapy and Biomarkers, together about 21.3% of its articles. Its main subfields are Cancer Research. (generated from OpenAlex topic counts and CAS ranking data)
Biomolecules and Biomedicine (formerly the Bosnian Journal of Basic Medical Sciences, BJBMS) is a comprehensive, multidisciplinary open-access medical journal dedicated to the advancement of medical research, practice, and education. The journal publishes pioneering research across the spectrum of pre-clinical studies, translational medicine, and clinical research, thereby advancing our collective knowledge in the realm of health and disease.
From the journal's Aims & Scope
Research area (LetPub): MEDICINE, RESEARCH & EXPERIMENTAL
Editor-in-chief Nicolai Wewer AlbrechtsenPublisher website
Editorial board by country: 3 in mainland China (about 4%); most named United States 16, Croatia 8, United Kingdom 5, Türkiye 5, Italy 4 (68 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Ferroptosis and cancer prognosisMedicine7.6%
- Inflammatory Biomarkers in Disease PrognosisMedicine7.2%
- Cancer Immunotherapy and BiomarkersMedicine6.5%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology6.1%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology5.7%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology4.7%
- Cancer, Lipids, and MetabolismBiochemistry, Genetics and Molecular Biology4.3%
- COVID-19 Clinical Research StudiesMedicine4.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 2.8Publisher website ·
- CiteScore 2026-06
- 4.7LetPub ·
- CiteScore (publisher)
- 5.2Publisher website ·
- SJR 2026-06
- 0.85LetPub ·
- SNIP 2026-06
- 0.84LetPub ·
- h-index
- 37OpenAlex ·
- i10-index
- 263OpenAlex ·
- 2-year mean citedness
- 3.11OpenAlex ·
- Self-citation rate
- 3.6%LetPub ·
- Share of gold OA articles
- 99.68%LetPub ·
Volume
- Articles per year
- 215LetPub ·
Articles by year OpenAlex count · 1,100 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 163 | 163 | 41 |
| 2025 | 214 | 214 | 660 |
| 2024 | 235 | 235 | 1,203 |
| 2023 | 134 | 134 | 1,144 |
| 2022 | 55 | 55 | 716 |
| 2021 | 14 | 14 | 190 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
57 daysMedian, submission to acceptance · P25–P75 39 days – 70 days
- Acceptance to online
- median 8 days (106 articles)
- Submission to online
- median 66 days
- Sample
- 106 articles with submission and acceptance dates (545 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Submission to publication (journal-reported)
- about 4 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 1,195 | Yes | CC BY | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare2 items from the author guidelines
- Keywords
- ≥ 3
- Suggested reviewers
- Optional
Article types accepted7
- hypothesisBiomolecules and Biomedicine considers the following article types. Authors should select the category that best fits their work. The Editors may reclassify a s…Length not stated
- meta-analysisBiomolecules and Biomedicine considers the following article types. Authors should select the category that best fits their work. The Editors may reclassify a s…Length not stated
- opinionBiomolecules and Biomedicine considers the following article types. Authors should select the category that best fits their work. The Editors may reclassify a s…Length not stated
- original researchBiomolecules and Biomedicine considers the following article types. Authors should select the category that best fits their work. The Editors may reclassify a s…Length not stated
- protocolBiomolecules and Biomedicine considers the following article types. Authors should select the category that best fits their work. The Editors may reclassify a s…Length not stated
- reviewBiomolecules and Biomedicine considers the following article types. Authors should select the category that best fits their work. The Editors may reclassify a s…Length not stated
- systematic reviewBiomolecules and Biomedicine considers the following article types. Authors should select the category that best fits their work. The Editors may reclassify a s…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review
- AI use Artificial intelligence tools usage
Biomolecules and Biomedicine recognizes the utility of artificial intelligence (AI), such as large language models (LLMs) and generative AI, in assisting with manuscript preparation. However, the critical and creative thinking of human researchers is irreplaceable. AI should complement, not substitute, human intellect in scientific writing. Guidelines Disclosure: Authors must disclose the use of A…
Source ↗Publisher website ·- Authorship Authorship and Contributor Policy
Alignment with standards Biomolecules and Biomedicine (“BiomolBiomed”) adheres to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. Authorship is limited to individuals who meet all four ICMJE criteria below. All authors must register their ORCID iD in the submission system and complete disclosures as required. ICMJE Recommendatio…
Source ↗Publisher website ·- Conflicts of interest Data sharing and disclosure
with service providers: We may share personal information with trusted third-party service providers who assist in journal operations (e.g., manuscript tracking systems, website hosting, digital archiving services). These providers are contractually obligated to protect your data and use it only for authorized purposes.with academic databases and indexing services: Author and publication details m…
Source ↗Publisher website ·- Data availability Data sharing and disclosure
with service providers: We may share personal information with trusted third-party service providers who assist in journal operations (e.g., manuscript tracking systems, website hosting, digital archiving services). These providers are contractually obligated to protect your data and use it only for authorized purposes.with academic databases and indexing services: Author and publication details m…
Source ↗Publisher website ·- Publication ethics Publication Ethics and Publication Malpractice Statement
Our Publication Ethics and Publication Malpractice Statement is based on the "Codes of Conduct and Best Practice Guidelines" developed by the Committee on Publication Ethics (COPE) (http://publicationethics.org/resources/code-conduct). The International Standards for Editors and Authors were developed at the 2nd WCRI (see http://publicationethics.org/resources/international-standards-for-editors-a…
Source ↗Publisher website ·- License & copyright Copyright Notice
Biomolecules and Biomedicine applies the Creative Commons Attribution (CC-BY) license to published articles. Under this license, authors retain ownership of the copyright for their content, but they allow anyone to download, reuse, reprint, modify, distribute and/or copy the content as long as the original authors and source are cited. Appropriate attribution can be provided by simply citing the o…
Source ↗Publisher website ·- Open access Institutional Open Access Membership Program (IOAMP)
This program allows APC discounts if the corresponding author's institution participates in our Institutional Open Access Membership Program. Partial or all of the publication costs may be covered by the author's institution at a reduced APC (more details are available at the IOAMP page). Top of page ⤴
Source ↗Publisher website ·- Peer review Peer review
Once a manuscript is submitted, it is assigned to the Editor most appropriate to handle it, based on the subject of the manuscript and the availability of the Editors. If the Editor determines that the manuscript is not of sufficient quality to go through the normal review process or if the subject of the manuscript is not appropriate to the journal's scope, the Editor rejects the manuscript with …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Association of Basic Medical Sciences of FBIH
- ISSN
- 2831-0896
- Electronic ISSN
- 2831-090X
- Society / sponsor
- Association of Basic Medical Sciences of FBIH
- Latest issue on the website
- Volume 26, Issue 9 (2026)
- Official links
- Journal homepage ↗DOAJ
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Biomolecules and Biomedicine
What CAS zone is Biomolecules and Biomedicine in?
In the 2025 upgraded edition of the CAS Journal Ranking, Biomolecules and Biomedicine is in Zone 4 of Medicine, and in Zone 4 of the minor category Medicine, Research & Experimental. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Biomolecules and Biomedicine?
The journal's website gives an impact factor of 2.8 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 4.7, h-index 37.
How long does peer review take at Biomolecules and Biomedicine?
Based on the dates recorded on 106 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 57 days (interquartile range 39–70 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Biomolecules and Biomedicine?
According to the journal's author guidelines: Keywords: ≥ 3; Suggested reviewers: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Biomolecules and Biomedicine based?
Of the 68 board members whose country the journal's board page names, 3 (about 4%) are in mainland China; the countries named most often are United States (16), Croatia (8) and United Kingdom (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Biomolecules and Biomedicine?
According to LetPub and DOAJ records, Biomolecules and Biomedicine is indexed in SCIE, Scopus and DOAJ.
Is Biomolecules and Biomedicine open access, and what is the APC?
Biomolecules and Biomedicine is a fully open-access journal. APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .